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concerning intragenic and/or extragenic SNPs. Maternal cell contamination is also
evaluated.
Results: Since 1998 a total of 52 at-risk couples have been supported by the Centro
di Riferimento Regionale Toscano per la Diagnosi Genetica di Fibrosi Cistica. On
44 out of 52 couples, a prenatal test has been performed. Affected fetus resulted
in 9 pregnancies; 2 resulted in a fetal loss after the prenatal sampling, the other
couples have decided for a fetus termination. 3 out of 8 couples, which have chosen
not to proceed with prenatal diagnosis, had spontaneous abortions; 4 out of 8 had
not affected or heterozygous children and only one had two affected children from
two different pregnancies.
Conclusions: The aim of the genetic counselling, which is an important step in
the CF diagnostic iter, is to offer at-risk couples the information concerning CF
hereditary pattern and to evaluate the recurrence risk. Considering that the majority
of couples ask a prenatal screening after the birth of an affected child, in order
to program the other pregnancies it is fundamental for laboratories to optimize the
different methods necessary for CF testing.
The success of CF prenatal diagnosis and other congenital diseases depends on the
effectiveness of a multidisciplinary approach as well as on the genetic counselling.
P17 b-DEFENSIN-1 GENE POLYMORPHISMS IN CYSTIC FIBROSIS
LUNG DISEASE
T. Santostasi, R. Tesse, A. Polizzi, L. Mappa, A. Manca, F. De Robertis,
O. Silecchia, V.P. Logrillo, L. Armenio. Department of Biomedicina dell’Eta`
Evolutiva, Pediatric Unit “S. Maggiore”, University of Bari, Italy
Introduction: Lung disease and Pseudomonas aeruginosa (P. aeruginosa) airway
colonization represent a major cause of morbidity and mortality in cystic ﬁbrosis
(CF). Human b-defensin (hBD)-1 is believed to play an important role in mucosal
innate immunity in the lung.
Objective: This study aimed to investigate whether single nucleotide polymor-
phisms (SNPs) of the DEFB1 gene, coding for hBD-1, were associated with
P. aeruginosa airway colonization in CF.
Methods: A total of 182 CF patients bearing the severe/severe CFTR genotype
(carriers of classes I, II, III of CFTR gene mutations) were studied. The SNPs
G-52A, C-44G and G-20A in the 5’-untranslated region of the DEFB1 gene were
genotyped by use of polymerase chain reaction and restriction fragment length
polymorphism. Patients’ sputum samples were collected and analyzed by standard
methods.
Results: We found that carriers of the GA and AA genotypes at the −52 locus site
of the DEFB1 gene had an increased risk of P. aeruginosa chronic colonization than
carriers of the GG genotype (OR adjusted for age 3.21, 95% CI 1.12−9.23, p = 0.03).
Carrying the −44CC and the −20GG genotypes was not related to an increased risk
of colonization with P. aeruginosa as compared to carriers of the −44CG/GG and
the −20GA/AA genotypes, respectively, in this population (ORs adjusted for age
1.37, 95% CI 0.26−7.22 and 0.43, 95% CI 0.13−1.42, respectively; p=ns). Moreover,
in this group of CF patients the ACG haplotype was also signiﬁcantly associated
with P. aeruginosa chronic infection (OR adjusted for age 2.70, 95% CI 1.15−6.36,
p = 0.02).
Conclusion: These results indicate that variant alleles in DEFB1 might contribute
to the colonization of P. aeruginosa in CF.
P18 MUTATIONS AND POLYMORPHISM INTERFERING WITH
PCR/OLA/SCS ASSAY
A. Stamato1, F. Narzi1, A. Amato1, S. Pierandrei2, M. Lucarelli2, R. Strom2,
S. Quattrucci1, L. Narzi1. 1Centro Fibrosi Cistica Regione Lazio – Clinica
Pediatrica – 2Dip. Biotecnologie Cellulari ed Ematologia – Universita` di Roma
“La Sapienza”, Rome, Italy
We report four cases of anomalous electropherograms obtained after PCR/OLA/SCS
analysis (Abbott), that led to the identiﬁcation of (a) three mutations: two considered
new mutations (E479X, G1247R(G>C)) and another mutation previously described
(I506V); (b) one polymorphism (2752−15C>G) all interfering with this analytical
procedure.
E479X and G1247R mutations were found in two CF subjects who, after
PCR/OLA/SCS, appeared homozygous for F508del and W1282X, although parents’
allelic segregation showed that the F508del and the W1282X mutations were present
in heterozygosity in one parent but absent in the other. Cycle sequencing (Applera)
of exons 10 (E479X) and 20 (G1247R) showed that these subjects were compound
heterozygotes F508del/E479X and W1282X/G1247R(G>C).
E479X mutation originates by nucleotidic change G>T at 1567 in exon 10 with
consequent Glu to Stop change at 479. This CF patient was diagnosed at 1 year
of age by symptoms; he is PI, with sweat chloride at 106mmol/l and moderate
pulmonary disease.
The aminoacidic substitution G1247R has already been described as a disease-
causing CFTR mutation originated by nucleotidic substitution 3871G>A; in this
case, instead, it originates from a 3871G>C nucleotidic substitution, with conse-
quent Glu to Arg change at 1247. This is a causing disease mutation and was found
in a CF patient diagnosed by neonatal screening; she is PS with sweat chloride at
78mmol/l and mild pulmonary disease.
The I506V mutation (previously reported as polymorphism 1648AorG) was found
in the mother of a heterozygous newborn carring F508del. This parent appeared
homozygous for F508del mutation while cycle sequencing of exon 10 showed that
she was compound heterozygous F508del/I506V. Also 2752−15C>G polymorphism
was found during parents’ allelic segregation of a heterozygous newborn carring
2789+5G>A. The mother appeared homozygous for 2789+5G>A mutation while
cycle sequencing of exon 14b (and proximal intronic regions) showed that this
subject had 2789+5G>A on an allele and 2752−15C>G on the other one.
Anomalous electrophoretic patterns of PCR/OLA/SCS assay and inconsistent par-
ents’ allelic segregation have to be checked for sequence variations, possibly
interfering with PCR primers or OLA probes; this should radically reduce wrong
genetic characterizations.
S.P was partially supported by a grant of “Associazione Laziale Fibrosi Cistica”.
P19 DIRECT SEQUENCING OF CSTs IN CYSTIC FIBROSIS PATIENTS
BEARING UNDEFINITE GENOTYPE
A. Elce, R. Tomaiuolo, A. Boccia, G. Paolella, G. Castaldo. CEINGE-Advanced
Biotechnologies, scarl, Naples; Dept. of Biochemistry and Medical Biotechnology,
University of Naples “Federico II”, Naples, Italy
Introduction: The regulation of the CFTR gene expression has been object of
numerous studies, because in a percentage of CF patients the disease is caused by
alteration of the expression. The analysis of CFTR sequences revealed the absence
of TATA box, but the presence of multiple transcriptional sites. In 2001, a tissue-
speciﬁc DNase I hypersensitive site (DHS) in intron 1 (185+10 kb) of the CFTR
gene was identiﬁed that is required for CFTR expression in the intestinal epithelium,
and other intronic sites are target of regulatory factors. Other still unknown targets
of regulatory factors may be present in CFTR introns. Recently, a comparative
analysis (Homo Sapiens, Mouse, Rat, Zebraﬁsh, Fugu) revealed the presence of a
high number of conserved sequences in human genome. Our group identiﬁed the
‘conserved sequence tags’ (CSTs), i.e., genomic sequences that may be the result
of selective evolutionary pressure for conservation due to a possible functional
role (Boccia A, et al. Nucleic Acid Res, 2005). CST sequences show at least 70%
identity between human and mouse over a length of 100bp. Mutations in these
regions could be responsible of genetic diseases. About 100 CSTs were found in
coding and non-coding regions of CFTR.
Aims: To analyse 52 CFTR intronic CSTs in 37 CF patients bearing one or both
undetected mutations after CFTR gene scanning. CF patients with a known genotype
(n: 23), and non-CF subjects (n: 20) were included in the study as controls.
Methods: We performed multiplex PCR followed by direct sequencing of the 52
CSTs on the DNA extracted from the 90 subjects included in the study.
Results: The study demonstrated that 57.6% of the analysed regions did not show
changes, while in 42.3% of the regions were observed 41 gene variants, including
16 novel. Eleven variants (most novel) were speciﬁcally present in CF patients
bearing undetected mutations. Furthermore, we identiﬁed three novel intragenic
microsatellites: one CA repeat in IVS10 and two PolyA in IVS3 and IVS4
respectively, with a high heterozygosity.
Conclusion: CSTs gene variants might represent causative-mutations; to verify this
hypothesis we will undertake both computational analysis (with known regulatory
motif) and in vitro studies with the “ﬁshing for partners” strategies. The three novel
intragenic microsatellites can be used to improve CF linkage diagnosis.
Acknowledgments: Cystic Fibrosis Foundation of Verona, Italy, is gratefully
acknowledged.
P20 MOLECULAR ANALYSIS OF GENES ENCODING CFTR
INTERACTORS OF SLC26 FAMILY IN CF PATIENTS:
PRELIMINARY RESULTS
R. Tomaiuolo1, G. Cardillo1, A. Elce1, C. Bellia2, V. Raia3, G. Castaldo1.
1CEINGE-Advanced Biotechnologies, scarl, Naples; Dept. of Biochemistry and
Medical Biotechnology, University of Naples “Federico II”, Naples, Italy; 2Lab.
of Clinical Biochemistry, Faculty of Medicine, University of Palermo, Italy; 3Dept.
of Pediatrics, University of Naples “Federico II”, Naples, Italy
Introduction: The SLC26 (Solute Linked Carrier) are a gene family encoding
highly versatile anion exchangers, involved in many physiological processes, like
trans epithelial NaCl transport and bicarbonate secretion. Actually, about 10 proteins
belong to this family and some of them are related to human diseases, like
SLC26A3 that is the disease gene of a rare and severe form of chronic chloride
loosing diarrhoea (CLD). Two domains of SLC26A3 protein, the “STAS-like” and
PDZ domains, play a critical role in its activation and bicarbonate secretion. This
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secretory mechanism requires the presence of CFTR protein which, in turn, is
activated by the interaction with SLC26A3. The main defect in CF has long been
thought to be the reduced epithelial chloride transport. However, recent works
turned this theory on its head, showing that the primary defect in cystic ﬁbrosis
is the inability to activate bicarbonate-driven ﬂuid secretion caused by chloride-
bicarbonate exchange. This mechanism requires the involvement of both SLC26 and
CFTR intact proteins: they form a unique complex by a direct interaction between
SLC26A3 “STAS-like” and CFTR “R” domains and by an indirect interaction
between PDZ domains of both proteins connected by the “PDZ-Binding Protein”.
Aim: The aims of the study were to evaluate if mutations in genes encoding some
SLC26 proteins (all characterized by the STAS-like and PDZ domains) may reduce
the the interactions between SLC26 genes (A3, A6, A7, A8 and A9) and CFTR
proteins, thus reducing the activation of CFTR. In other words mutations of SLC26
genes might be causative of CF.
Patients and methods: We analyzed, by direct sequencing, 25 patients bearing CF
and 25 patients bearing CFTR related disease, with one or both undetected CFTR
mutations. Furthermore, 100 non CF alleles were analyzed as controls.
Results and conclusions: For SLC26A3 we identiﬁed two mutations and two
intronic variants in CF patients. Similarly, for the other four genes, we identiﬁed
a number of gene variants, some of which speciﬁcally present in CF patients,
suggesting a possible role of SLC26A genes in the pathogenesis of CF.
Acknowledgements: Grants from the “Fondazione per la ricerca sulla Fibrosi
Cistica (Verona)” is gratefully acknowledged.
P21 INVESTIGATION OF CFTR ESONIC REARRANGEMENTS IN
INFERTILE COUPLES
S. De Toffol, B. Malvestiti, F. Dulcetti, A. Ruggeri, A. Maggioni, M. Di Lernia,
F. Maggi, G. Simoni, F.R. Grati. Research and Development, Cytogenetics and
Molecular Biology, TOMA Advanced Biomedical Assays S.p.A., Busto Arsizio,
Varese, Italy
Cystic Fibrosis (CF) is the most common monogenic autosomal recessive disease in
Caucasians. In Italy, couples approaching assisted reproduction techniques (ART)
are usually subjected to the ﬁrst level CFTR mutation screening due to the high
frequency of CFTR carriers in general population (1/27, 3.7%); in addition, men
with congenital bilateral absence of vas deferens (CBAVD) and those with alter-
ations in spermatogenesis present CFTR mutations (70−88% and 7%, respectively).
Large CFTR gene rearrangements account for 1.5% of frequency in CF patients
with classical manifestations and 1% in CBAVD men.
The aim of this work was to understand if CFTR esonic rearrangements could be
a further possible cause of infertility.
Twenty-seven WT partners, belonging to discrepant couples after CFTR mutation
screening and scanning, were investigated for the presence of esonic rearrange-
ments by using QMPSF and MLPA analyses. In this preliminary study no large
esonic rearrangements were found. Our future perspectives are to add the esonic
rearrangements analysis to the ﬁrst level mutation screening in order to investigate
a larger cohort of patients.
P22 EMERGING PATHOGENS IN CYSTIC FIBROSIS: TEN YEARS
FOLLOW UP
L. Spicuzza, C. Sciuto, G. Di Dio, L. Bivona, G. Cassisi, M. La Rosa.
Broncopneumologia Pediatrica, Dipartimento di Pediatria, Universita` di Catania,
Catania, Italy
Cystic ﬁbrosis (CF) is characterized by speciﬁc age-related pathogens. Among
emerging pathogens in recent years a higher prevalence has been found for
Burkholderia cepacia, Stenotrophomonas maltophilia and Achromobacter xylosox-
idans.
Aim of our retrospective study was to establish the prevalence of CF commonly
associated and emerging pathogens in a cohort of patients followed in our Cystic
Fibrosis Unit for ten years. We studied a total of 109 patients (51 males, 42%
children, 58% adults) followed in our Unit from January 1996 to December 2006.
For each patient clinical records were examined, with microbiological ﬁndings and
respiratory functional data. The highest prevalence of Ps.aeruginosa, was observed
in 2004 (58%), followed by a clear decrease in the following years with the
lowest rate recorded in 2006 (40.3%). The prevalence of St.aureus showed a highly
irregular trend. The lowest prevalence was observed in 2004 (24%), with an increase
recorded in the following years, with a maximum value recorded in 2006 (63%). We
observed a clear increase in the prevalence of B. cepacia in the biennium 1996–1998
(13%) with a successive reduction to 5% in 2006. First isolations of A.Xylosoxidans
were observed in 2002–2004 with a maximal prevalence of 3% and a reduction in
the following years. None of the patients had a positive sputum for S. maltophilia
until 2002. The prevalence of this pathogen progressively increased to 8% in 2004.
In our population B.Cepacia has been associated to more severe clinical conditions
characterised by a more rapid decline in FEV1 (mean FEV1 = 45.7%) and a rapid
progression to respiratory failure (occurring in 25% of the patients with B.Cepacia).
S.Maltophilia exhibited a mild effect on respiratory function (mean FEV1= 67%)
and respiratory failure was present in 16.7% of the patients.
Generally, emerging pathogens have been observed only in the adult population.
P23 MOLECULAR EPIDEMIOLOGY OF STENOTROPHOMONAS
MALTOPHILIA (SM) IN THE CYSTIC FIBROSIS (CF) CENTRE OF
GENOVA
M. Mentasti, P. Morelli, G. Melioli, G. Manno. General Laboratory of Analysis,
“Giannina Gaslini” Institute, Genova, Italy
Background: SM (previously known as Pseudomonas maltophilia and then as
Xanthomonas maltophilia) is a non-fermentative, oxidase negative, Gram negative
bacillus, intrinsically resistant to carbapenems, virtually resistant to all beta-lactams
and often multiresistant. It has emerged as an important pathogen, particularly in
immunocompromised patients and it is also frequently isolated from airway samples
of CF patients; anyway its pathogenic role still remains not clearly understood.
Aim: The purpose of this study is to investigate if a patient to patient transmission
and/or an environmental acquisition has occurred among CF patients in follow up
at the CF centre of “Giannina Gaslini” Institute, Genova.
Materials and Methods: Since June 2004 a large collection of SM non-repetitive
strains has been set up at the General Laboratory of Analysis, it comprises 91 strains
isolated from 91/220 (41.4%) CF patients chronically/intermittently/sporadically
colonized, 39 strains from non-CF patients and 25 strains from environmental
sources (both hospital and community environment) for a total of 115 strains.
22/91 strains isolated from CF patients have been preliminarily analyzed. Genetic
ﬁngerprinting was performed by BOX-PCR according the protocol published by
Rademaker J.L. et al in 1998 using BOX-A1R primer. SM ATCC 13637 was used
as quality control strain. Cluster analysis was performed by Gel Compare II using
Pearson’s coefﬁcient.
Results: BOX PCR analysis generated a good resolution of molecular proﬁles,
allowing to perform an efﬁcient analysis by Gel Compare II. Among the 22 CF
analyzed strains a total of 12 different genotypes were found: 6 (50%) were not
shared among patients while the other 6 (50%) were shared by 3 groups of 2
patients, 1 group of 3 patients and 1 group of 4 patients.
Conclusions: BOX PCR is a suitable method to determine the genetic relatedness of
SM from CF patients. Although these are preliminary results, the data show clearly
that SM seems to easily circulate among patients, as one half of the analysed strains
are shared. Moreover, for a better comprehension, besides analysing the remaining
CF strains it will be fundamental to analyze the non-CF and the environmental
strains in order to establish if highly transmissible strains are circulating inside the
hospital and/or an environmental acquisition has occurred.
P24 EMERGENCE OF COLISTIN-RESISTANT PSEUDOMONAS
AERUGINOSA FROM ITALIAN CYSTIC FIBROSIS PATIENTS
G. Manno1, P. Morelli1, M. Mentasti1, R. Casciaro2, G.M. Rossolini3, N. Cirilli4,
R. Gagliaridini4, A. D’Aprile5, F. Gioffre`6, D. Scuteri6, G. Melioli1. 1Microbiology
Lab., 2Cystic Fibrosis Centre – Gaslini Genova, 3University of Siena, 4Cystic
Fibrosis Centre Ancona, 5Microbiology Lab. Cerignola, 6Microbiology Lab.
Soverato, Italy
Background: Colistin (CL) has emerged as a relevant therapeutic option for the
treatment of P. aeruginosa (PA) pulmonary infection in CF. The development of
resistance to this agent under selective pressure is not unexpected, even if it may
occur at lower extent compared with other antipseudomonal agents.
Objective:Monitoring the susceptibility to CL of a large collection of PA recovered
from Italian CF pts.
Methods: During 2006, 295 PA strains (151 non-mucoid and 113 mucoid and 31
SCV) from 178 pts from 4 Italian CF Centres (Genova, Ancona, Cerignola and
Soverato), were tested by CLSI disk diffusion method in Mueller–Hinton (MH)
agar (BD) for 12 antipseudomonal drugs and CL using a 10 mcg disk. (BD) with
PA 27853 ATCC as QC.
Isolates showing reduced susceptibility or resistance to CL disk were re-tested by
Etest method in MH agar, after at least 10 repeated sub-culture in blood agar. The
genetic relatedness of all isolates collection was previously determined by BOX-
PCR.
Results: Four PA isolates (1 mucoid, 1 non-mucoid and 2 SCV) from 4 patients (3
from Genova and 1 from Ancona) showed resistance to CL by disk diffusion and
conﬁrmed by Etest. The resistance level was high, with the Minimum Inhibitory
Concentration (MIC) ranging from 12 to 32mcg/ml. The 2 SCV strains were
multi-drug-resistant, while the mucoid isolate was susceptible to the other anti-
pseudomonal drugs tested. The CL-resistant PA isolates showed different genetic
proﬁles by BOX-PCR. 3/4 patients chronically colonized by CL-resistant PA had
several previous antibiotic treatments with aerosolised CL.
